BUFFALO GROVE, Ill.--(BUSINESS WIRE)--RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women’s health, today announced that Chief Scientific Officer David Sherris, Ph.D., will present scientific data on the Company’s proprietary RES-529 program in ophthalmology. Dr. Sherris’s presentation at the Cambridge Healthtech Institute conference is scheduled for Monday, October 6, 2014 at 4:55 pm (EDT) at the Westin Boston Waterfront Hotel.
RES-529 is a first-in-class inhibitor of the PI3K/Akt/mTOR pathway. Ocular disorders of retinal origin, as in wet age-related macular degeneration (AMD), have aberrant back of the eye vascularization. This aberrant vascularization is induced through a process known as angiogenesis. Numerous pro-angiogenic factors have been shown to reside in the eyes of patients with wet AMD. Many of such pro-angiogenic factors activate the PI3K/Akt/mTOR pathway ultimately resulting in aberrant back of the eye vascularization. One such factor is vascular endothelial growth factor (VEGF). Anti-VEGF technologies (Lucentis®, Eylea®) have been used successfully to treat wet AMD. However, a significant number of patients show minimal activity or are refractory to anti-VEGF treatment. As there are numerous pro-angiogenic factors in the eye of AMD patients in addition to VEGF, an agent having broader activity to inhibit multiple pro-angiogenic factors may be useful for treatment of such patients. RES-529 has been shown to inhibit a wide variety of pro-angiogenic factors. For this reason, RES-529 treatment was evaluated in two Phase I human clinical studies in wet AMD alone and in the presence of Lucentis®. Final results will be presented here indicating a lack of toxicity and preliminary evidence of activity.
“As anti-VEGF technologies have shown some limitations, combination therapy with such agents may provide additional support. We have shown RES-529 to have broader anti-angiogenic activity, a longer half-life in the eye and a less invasive administration than anti-VEGF technologies. For these reasons, we believe RES-529 could be a next generation agent for combination therapy with anti-VEGF technologies,” said Dr. Sherris.
RES-529 was developed from a non-steroidal, small molecule drug library through computational design, synthetic and medicinal chemistry. Through a series of in vitro and in vivo animal models, RES-529 has been shown to have activity in several disease indications due to its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway, specifically as a first-in-class allosteric, dissociative inhibitor of both TORC1 and TORC2.
About RestorGenex Corporation
RestorGenex Corporation is a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women’s health. The Company is reviewing and intends to continue to review its products and technologies. The Company’s prescription dermatology business primarily is based upon Company compounds under development for the treatment of keloid scarring and androgen excess, e.g. acne and hirsutism (unwanted excess hair). The Company’s ophthalmology product, RES-529, will target age-related macular degeneration, based on inhibition of the PI3K/Akt/mTOR pathway. The Company’s prescription women’s health business is based upon a “soft” estrogen compound under development for vulvar and vaginal atrophy (VVA), a condition affecting peri- and post-menopausal women due to declining levels of estrogen. www.restorgenex.com
Certain statements in this release are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about RestorGenex’s participation at the Cambridge Healthtech Institute conference, the future performance and success of RES-529, RestorGenex’s intent to review its products and technologies and other statements that are not historical in nature, particularly those that utilize terminology such as “will,” “believe,” “could,” “may,” “intends,” “expects,” “future,” “continue,” other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause RestorGenex’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include, among others, uncertainties regarding the future performance and success of RES-529, uncertainties regarding RestorGenex’s ability to license out its existing products and technologies and license in additional products and technologies and the terms of such licenses; uncertainties involved in clinical testing, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance and other risks and uncertainties described in RestorGenex’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K/A, subsequent quarterly reports on Form 10-Q and final prospectus dated July 31, 2014. All forward-looking statements in this release speak only as of the date of this release and are based on RestorGenex’s current beliefs and expectations. RestorGenex undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.